Solid tumour-induced systemic immunosuppression involves dichotomous myeloid–B cell interactions
Xiaoxin Hao(Baylor College of Medicine), Xiang H.-F. Zhang(Baylor College of Medicine), Azadeh Nasrazadani(The University of Texas MD Anderson Cancer Center), Hilda L. Chan(Baylor College of Medicine), Yang Gao(Baylor College of Medicine), Yunfeng Ding(Baylor College of Medicine), Che-Hsing Li(Houston Methodist), Bora Lim(Baylor College of Medicine), Liqun Yu(Baylor College of Medicine), Angela Alexander(The University of Texas MD Anderson Cancer Center), Ling Wu(North Carolina Central University), Zhan Xu(Baylor College of Medicine), Naoto T. Ueno(Breast Cancer Care), Jun Liu(Tongji University), Weijie Zhang(Nanjing Medical University), Nan Chen(Shanghai Normal University), David G. Edwards(University of Delaware), Fengshuo Liu(Baylor College of Medicine), Yichao Shen(Baylor College of Medicine)
Cited by 16
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927